BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 28536128)

  • 1. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
    Goldberg N; Fralick M
    CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 3. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
    Dalama B; Biagetti B; Mesa J
    Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 5. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Ghosh A; Gupta R; Misra A
    J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
    Suissa S
    Circulation; 2018 Apr; 137(14):1432-1434. PubMed ID: 29610125
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Introduction].
    GarcĂ­a SD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
    [No Abstract]   [Full Text] [Related]  

  • 9. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
    Bloch MJ
    J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
    [No Abstract]   [Full Text] [Related]  

  • 10. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

  • 11. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
    Miller K; Miller EM
    J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2-inhibitors in type-2 diabetes: The remaining questions!
    Rajput R; Ved J
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S433-S438. PubMed ID: 28395977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Association for the Study of Diabetes 51st Annual Meeting.
    Gao HX; Regier EE; Close KL
    J Diabetes; 2016 Mar; 8(2):177-80. PubMed ID: 26606912
    [No Abstract]   [Full Text] [Related]  

  • 15. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 16. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
    Mehr SR; Zimmerman MP
    Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
    [No Abstract]   [Full Text] [Related]  

  • 18. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
    Bell RM; Yellon DM
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):435-437. PubMed ID: 29030201
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.